Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis-Reference-Cited by-同舟云学术

Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis

Published:2015-06 Issue:3 Volume:94 Page:261-269
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Nunes Altacílio Aparecido,da Silva Anderson Soares,Souza Kathiaja Miranda,Koury Christine de Nazaré Silva,de Mello Luane Marques

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference38 articles.

1. Signaling pathways activated by the B-cell receptor in chronic lymphocytic leukemia;Scupoli;Expert Rev Hematol,2012

2. Risk of developing chronic lymphocytic leukaemia is influenced by HLA-A class I variation;Di Bernardo;Leukemia,2013

3. Small lymphocytic lymphoma and chronic lymphocytic leukaemia: are they the same disease?;Santos;Cancer J,2012

4. Chronic lymphocytic leukaemia;Rozman;N Engl J Med,1995

5. Therapy of chronic lymphocytic leukaemia;Hallek;Best Pract Res Clin Haematol,2010

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study;British Journal of Haematology;2021-02-19

2. Astragalus polysaccharides and astragaloside IV ameliorates cyclophosphamide-induced mouse model of overactive bladder;Taiwanese Journal of Obstetrics and Gynecology;2020-03

3. Adverse Cutaneous Reactions to Chemotherapeutic Agents;Hospital-Based Dermatopathology;2020

4. Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study;Leukemia;2019-08-27

5. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study;Haematologica;2018-07-05